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Introduction
Non-communicable diseases (NCDs) are among the lead-
ing causes of death around the globe. Due to major changes 
in fertility and life expectancy, the world’s population is 
growing rapidly and non-communicable diseases includ-
ing cancers are accordingly increasing significantly  [1]. 
According to WHO estimates in 2015, cancer is the first 
or second leading cause of mortality before the age of 70 
in most countries. Population growth, aging, and economic 
development are among the reasons for the growing preva-
lence of cancer worldwide. Cancers are the leading cause of 
death in some developed countries and the second leading 
cause of death after cardiovascular disease in the develop-
ing countries [2]. Ovarian cancer is ranked seventh of the 
most common cancers among women thus accounting for 
about 4% of all cases associated with the females; it is the 
sixth malignant cause of cancer deaths in women [3]. As for 
its high prevalence, high mortality rate and its impact on pa-
tients’ quality of life and economic costs, ovarian cancer is 
known to be one of the important abnormalities that require 
special attention [4]. 
Among the most significant factors triggering the incidence 
of ovarian cancer is family history, pregnancy, childbirth 
and age [5, 6]. Environmental and socioeconomic factors 
also affect ovarian cancer mortality rate. The overall grow-
ing trend of ovarian cancer incidence and mortality can be 
observed in all regions of the world across different social 
and economic levels. Variations in ovarian cancer incidence 
rate in the world is not restricted to the above factors. It can 
also be due to differences in the cancer registration system 
in different countries [7]. 
Socio-economic developments can bear profound impact 
on the scale and features of cancer. The epidemiological 
transmission of cancer distribution around the world has 
virtually changed. Compared to high-income nations, the 
prevalence of global demographic and epidemiological 
trends in middle- and low-income countries has shown a 
crucial cancer decline in recent decades. In some regions 
of Africa, the standardized prevalence of ovarian cancer is 
lower than 5 per 100,000 whereas in eastern and central 
Europe it proves to be higher than 11 per 100,000 among 
women [4, 8]. 
Annually, 225,000 new cases of ovarian cancer are di-
agnosed 140,000 of whom die out [9]. The risk of com-
plications resulting from this cancer is 1 in 71 and the 
chance of death amounts to 1 in 95 [9, 10]. Moreover, 
estimates of the disability-adjusted life-years (DALYs) 
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lost in ovarian cancer are on the rise [11]. Ovarian can-
cer is more common in industrialized than in the de-
veloping countries. However, the highest proportion of 
age-specific mortality in ovarian cancer is seen in the 
developing countries [12]. According to the United Na-
tions record on HDI, the disease burden associated with 
ovarian cancer in areas with a high HDI proves higher. 
HDI is a summary index for human development meas-
urements; it measures the mean achievement of a coun-
try in three main dimensions of human development: 
long and healthy life, access to knowledge and living 
standards [13]. 
In regard with the global trend of ovarian cancer and its 
progress in recent years, awareness to its incidence and 
mortality and its relation to the HDI can be effective in 
planning and managing financial and human resources 
for its prevention. Despite the increasing burden of can-
cers in the developing countries, only 5% of global re-
sources are appropriated for these countries [14]. It thus 
seems a requisite for all nations to conduct further re-
search so as to uncover how socioeconomic conditions 
can affect the cancer risk factors. 
The purpose of this study is to assess the impact of socio-
economic development (based on HDI) on the global trend 
of incidence and mortality resulting from ovarian cancer in 
the world based on Global Cancer Data for 2018. We in-
tend to measure the key characteristics of ovarian cancer 
transmission in the world by examining the relationship be-
tween the incidence rate and the HDI, which consists of life 
expectancy, education, and gross national income.
Material and methods
Methods used for measuring incidence rate in terms 
of age and gender for each country are touched upon 
broadly as follows: 1) national incidence rate observed 
by 2018 (45 countries); 2) the most recent (national or 
regional) incidence rates on the basis of the population 
in 2018 (50 countries); 3) rates calculated using national 
mortality data through modeling and the ratio of mor-
tality to incidence rate obtained from cancer records of 
countries (14  countries); 4)  rates calculated using na-
tional mortality data through modeling and the ratio of 
mortality to incidence rate obtained from cancer records 
of neighboring countries (37 countries); and 5) national 
incidence rates in terms of age and gender for all cancers 
obtained by averaging the overall incidence rates from 
neighboring countries. These values were then analyzed 
to obtain the national incidence for each specific site 
using relative cancer frequency data (7 countries). Fur-
ther, the rates were calculated as the median of selected 
neighboring countries.
Mortality
The methods deployed for measuring incidence rate for 
each country as to age and gender are ranked as follows: 
1) the national mortality rate observed and published by 
2018 (81  countries); 2)  recent national mortality rates 
according to population in 2018 (20 countries); 3) rates 
calculated using national mortality data through mode-
ling and the ratio of mortality to incidence rate obtained 
from cancer records of neighboring countries (81 coun-
tries); 4) the rates calculated as the median of selected 
neighboring countries (three countries). 
Human Development Index (HDI)
Since 1990, a report called Human Development Report 
is published annually by the United Nations Develop-
ment Program in which countries are compared on vari-
ous indicators including education, health, as well as 
economic, social, environmental, political factors and 
the like. In the Human Development Report, countries 
are divided into groups of very high, high, moderate and 
low human development based on the Human Develop-
ment Index [15].
The HDI numerical value is known to be between 0 and 
1. This value reveals how much a country has attempted 
to achieve the highest possible value of 1 and also allows 
comparisons among the countries. The Human Develop-
ment Index (HDI) is a summary measure of the average 
achievement in three dimensions of human develop-
ment: having a long and healthy life, being knowledge-
able and bearing a decent standard of living. The HDI is 
the geometric mean of normalized indices for each of the 
three dimensions, which measures the success of each 
dimension. Life expectancy is measured by life expec-
tancy at birth, the education dimension is estimated by 
mean of years of schooling (elementary, secondary, and 
higher education), and living standard is measured by 
gross national income (GNI) per capita [16, 17].
Statistical analysis
In this study, the correlation bivariate method was used to 
assess the correlation between the incidence and mortal-
ity rates of ovarian cancer and the HDI. Linear regression 
models were also used to assess the HDI effect on the inci-
dence rate of ovarian cancer. Significance level was consid-
ered lower than 0.05. Data analysis was conducted by Stata 
software version 14. 
Results
Based on cancer record results in 2018, 8,622,539 new 
cancer cases and 4,169,387 cancer deaths were recorded 
in women; 1.72 were new cases (4.4%) while 184,799 
(2.08%) deaths were due to ovarian cancer. The highest 
number of new cancer cases and the highest death cases 
from ovarian cancer reported for Asia amounted to 153,075 
(51.8%) and 92,527 (50.01%), respectively (Fig. 1).
Table I sets out the incidence and mortality rate of ovarian 
cancer in each continent. The results indicated the highest 
ovarian cancer incidence in the world being in Serbia (16.6 
per 100,000), Brunei (16 per 100,000) and Belarus (15.4 
per 100,000), respectively. The highest mortality rates for 
ovarian cancer were identified in Samoa (12 per 100,000), 
Solomon Islands (8.4 per 100,000) and Poland (8.7 per 
100,000) (Tab. I, Fig. 2).
Z. KHAZAEI ET AL.
E176
Tab. I. Estimated age-standardized incidence and mortality rates due to ovarian cancer in the world in 2018 [source: GLOBOCAN 2018].
Country
Incidence Mortality
Age group Age group
0-49 50-85 0-49 50-85
CR ASR CR ASR CR ASR CR ASR
Afghanistan 1.5 2.2 13.1 13.1 0.93 1.5 12.4 12.5
Albania 2.1 1.6 12.6 12.7 0.53 0.42 7.1 6.6
Algeria 2.6 2.4 14.6 15 0.87 0.82 11.5 11.9
Angola 0.83 1.2 10.4 10.6 0.47 0.8 10.2 10.5
Argentina 3.8 3.3 27.2 25.9 1.1 0.94 18.3 16.1
Armenia 2.5 1.9 20.9 20.4 1.2 0.95 18.8 18.2
Australia 2.9 2.2 29.2 25.8 0.7 0.53 21.9 17.3
Austria 3.9 2.6 34.4 30.8 0.87 0.53 25.8 19.7
Azerbaijan 2.8 2.3 17.3 17.7 1.2 1 15.5 16.3
Bahamas 2.7 2 15.6 14.6 0.69 0.5 19 18.1
Bahrain 2.3 2.2 28 33 1 0.96 23.3 29.1
Bangladesh 2.4 2.2 10.5 10.8 1.5 1.4 9.1 9.5
Barbados 6.4 4.3 26.8 21.8 3.2 2.2 25 20
Belarus 11.4 7.9 44.3 45.6 1.9 1.3 18.4 17.7
Belgium 2.4 1.8 25.8 23.4 0.61 0.43 24.7 17.9
Belize 1.2 1.5 0 0 0.61 0.74 0 0
Benin 1.3 1.8 6.9 6.9 0.76 1.1 6.8 6.8
Bhutan 2.1 2.3 21.5 21.3 0.91 1.1 19.7 19.7
Bolivia, Plurinational State of 1.6 1.7 10.5 11.3 0.58 0.7 7 7.4
Bosnia and Herzegovina 6.6 4.4 34.3 34.5 1.4 0.93 23.6 22.2
Botswana 0.99 1.1 8.6 8.9 0.3 0.37 8.6 8.9
Brazil 2.6 2.1 16.6 15.9 0.94 0.76 12.4 11.7
Brunei 9.5 7.8 52.7 48.6 1.8 1.3 26.4 25.7
Bulgaria 7.9 5 34.6 34.8 3 1.9 25.1 22.9
Burkina Faso 1.3 1.8 9.9 9.9 0.85 1.3 9.8 9.8
Burundi 1 1.6 13.3 13.5 0.74 1.3 13.1 13.3
Cabo Verde 0 0 6.5 6.1 0 0 6.5 6.1
Cambodia 2.4 2.5 14.9 14.9 1 1.1 11.9 12.1
Cameroon 2.2 3.1 11.4 11.4 1.4 2.1 10.8 10.8
Canada 3.9 2.9 30.9 28.1 0.91 0.65 23.7 19.3
Central African Republic 1.7 2.5 14.8 14.9 1.3 2.1 14.8 14.9
Chad 2 3.2 17 17 1.4 2.5 17 17
Chile 3.5 2.8 22 21.5 0.96 0.75 14.5 13.4
China 4 2.8 15.4 15.5 1.1 0.72 11.5 11.4
Colombia 4.1 3.5 26.3 26.2 1.3 1.1 16.3 16.1
Continues
Fig. 1. Pie charts presenting the distribution of new cases and deaths due to ovarian cancer in 2018 for all age groups in different conti-
nents [source: GLOBOCAN 2018].
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Tab. I. Estimated age-standardized incidence and mortality rates due to ovarian cancer in the world in 2018 [source: GLOBOCAN 2018].
Country
Incidence Mortality
Age group Age group
0-49 50-85 0-49 50-85
CR ASR CR ASR CR ASR CR ASR
Comoros 0 0 6.5 6.1 0 0 6.5 6.1
Congo, Democratic Republic of 0.81 1.3 11.5 11.6 0.52 0.88 10.2 10.3
Congo, Republic of 1 1.4 13.1 13.2 0.46 0.64 12.7 12.9
Costa Rica 2.2 1.8 16.1 15.5 1 0.87 12 11
Croatia 7.3 4.9 42.3 40.6 2.1 1.4 30.9 26
Cuba 4.3 3.1 16.5 16.4 1.4 0.89 12.8 12.2
Cyprus 2.2 1.6 30.2 27.9 1.5 1.1 33.8 28.2
Czech Republic 4.9 3.1 38.7 35.3 1.8 1.1 34.9 29.1
Côte d’Ivoire 1 1.5 15.6 16.1 0.66 1 15.3 15.9
Denmark 2.5 1.8 33.1 29.5 0.99 0.69 30.7 24
Djibouti 3.1 3.2 21.8 21.9 1.7 1.8 21.8 21.9
Dominican Republic 1.3 1.3 7.9 7.9 0.34 0.34 6.7 6.6
Ecuador 2.9 2.7 22 21.3 0.98 0.95 14.8 13.9
Egypt 2.4 2.5 20.8 20.7 0.94 1 18.9 18.9
El Salvador 4.8 4.5 22 20.2 1.5 1.5 16.1 13.9
Equatorial Guinea 1.9 2.8 15.9 15.5 0.76 1.3 15.9 15.5
Eritrea 2.7 3.5 23.4 23.2 1.8 2.7 23.4 23.2
Estonia 5.4 3.6 41.6 36.9 1.6 1 36.8 28.5
Ethiopia 3.1 4.1 23.8 23.8 1.9 2.8 23.5 23.6
Fiji 8.8 8.3 27.6 27.9 2.8 2.8 21.5 21.6
Finland 2.9 2.3 32.2 27.9 0.76 0.58 25.6 19.2
France 2.8 2.1 32.5 27.4 0.74 0.54 27.7 19.5
France, Guadeloupe 3.5 2.7 25.3 25.8 1.4 0.78 16.2 13.6
France, La Réunion 2.9 2.3 25.6 24.8 0.64 0.49 12.4 11.3
France, Martinique 2.5 1.4 21 19.8 0.84 0.44 13.2 11.9
France, New Caledonia 5 3.9 36.7 37.2 0.99 0.73 15.7 16.9
French Guyana 0.84 0.85 38.4 39.1 0 0 23 22.9
French Polynesia 3.8 3.4 14.5 14.5 0 0 14.5 14.7
Gabon 2.1 2.5 13.1 12.2 1 1.3 13.9 12.8
The Gambia 0.1 0.16 2.1 2.1 0 0 2.1 2.1
Gaza Strip and West Bank 1.4 1.8 17.2 17.7 0.67 0.91 15.3 15.9
Georgia 2.9 2 21.9 21.4 1.3 0.93 19.6 18.5
Germany 3.2 2.2 31.1 27 1 0.66 26.5 20.1
Ghana 2.6 3.1 29.3 30 1.3 1.7 28.2 29.1
Greece 5.6 3.6 29.3 26.5 1.4 0.83 22.2 17.4
Guam 1.7 1.5 31.6 32.2 1.7 1.5 31.6 32.2
Guatemala 1.9 2.1 9.8 9.6 0.57 0.66 7.3 7
Guinea 0.88 1.2 7.9 7.9 0.59 0.89 8.1 8
Guinea-Bissau 1.3 1.8 11.8 11.6 0.81 1.2 11.8 11.6
Guyana 3.2 3.2 26.8 27.2 1.3 1.3 18.8 19.3
Haiti 2.8 2.8 7.7 7.8 1.8 1.8 7.4 7.6
Honduras 2.8 2.8 7.6 7.4 1.3 1.3 5.9 5.9
Hungary 8 5.1 49.7 45.6 2.3 1.4 33 27.6
Iceland 1.8 1.4 33.1 30.7 0 0 26.1 19.3
India 2.9 2.7 16.5 16.5 1.2 1.1 14 14.1
Indonesia 5 4.4 30.6 31.1 1.8 1.6 22.8 23.7
Iran, Islamic Republic of 2.2 1.9 13.8 14 0.59 0.54 8.9 9.3
Iraq 1.6 2 11.6 11.6 0.81 1 10.3 10.4
Ireland 4.3 3 49.1 45.1 1.2 0.88 35.5 28.5
Israel 1.9 1.7 22.6 20.9 0.87 0.81 25.5 21.2
Italy 5.5 3.5 28.4 26.1 1.3 0.74 21.1 16.7
Jamaica 4.2 3.7 27.1 25 1.5 1.3 23 20.3
Japan 8.7 5.7 24.5 25 1.8 1.1 14.6 12.2
Continues
Follows
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Tab. I. Estimated age-standardized incidence and mortality rates due to ovarian cancer in the world in 2018 [source: GLOBOCAN 2018].
Country
Incidence Mortality
Age group Age group
0-49 50-85 0-49 50-85
CR ASR CR ASR CR ASR CR ASR
Jordan 1.9 2.1 18.5 19.2 0.7 0.8 16.2 17
Kazakhstan 4.5 4 30.7 31 1.8 1.6 21.5 21.8
Kenya 1.6 2.1 23.8 24.7 0.79 1.1 23.4 24.3
Korea, Democratic Republic of 3.4 2.5 17.1 17.4 1.1 0.78 10.8 10.3
Korea, Republic of 5.4 3.7 18 17.8 1 0.62 10.6 9.5
Kuwait 1.7 1.3 14.3 17.7 0.65 0.49 11.9 16
Kyrgyzstan 3.7 3.8 24 24.3 1.4 1.6 19.3 19.9
Lao People’s Democratic 
Republic
2.6 2.8 17.5 17.6 1 1.2 13.6 13.9
Latvia 9.6 6.1 48.4 47 3 1.9 37 31.3
Lebanon 3.6 3.5 31.9 30.9 1.3 1.3 27.7 26
Lesotho 1 1.4 10.5 10.2 0.5 0.8 10.5 10.2
Liberia 1 1.4 12.5 12.5 0.65 0.95 12.5 12.5
Libya 2.5 2.2 15.3 15.3 0.59 0.51 11.1 11.3
Lithuania 7.7 5.1 42.8 40.6 3 1.9 36.3 31.3
Luxembourg 3.2 2.1 42.5 32.5 1.6 1 30.9 21.2
Madagascar 0.47 0.59 6.7 6.8 0.28 0.42 6.6 6.7
Malawi 1.6 2.2 8.1 8.2 0.96 1.5 8 8.1
Malaysia 3.7 3.4 26.3 26.3 1.5 1.4 19.9 20
Maldives 4.3 4 29.7 30.9 1.2 1.4 23.1 23.6
Mali 1.6 2.4 12.2 12.2 1 1.7 12.1 12.1
Malta 4 2.7 33.8 28.3 0 0 34.9 25.1
Mauritania 1.5 1.8 11.5 11.5 0.7 0.95 11.5 11.5
Mauritius 3.7 2.8 23.4 22.9 1.4 1 16.7 16.5
Mexico 4 3.5 20.2 20.2 1.4 1.2 15.5 15.2
Mongolia 2.5 2.3 14.6 14.7 1.1 1 10.3 11.2
Montenegro 1.5 1.1 24.7 24.6 0.5 0.37 15.3 13.4
Morocco 2.5 2.2 18.8 19.1 0.84 0.79 16.5 16.9
Mozambique 0.38 0.44 5.5 5.6 0.24 0.37 5.4 5.5
Myanmar 3.5 3.1 15.5 15.2 1.6 1.4 11.7 11.7
Namibia 0.86 1.1 11.8 12.2 0.35 0.47 11.2 11.7
Nepal 3.5 3.5 15.7 16.1 1.7 1.8 14.1 14.3
New Zealand 2.5 1.9 28.1 25.2 0.84 0.63 19.2 15.9
Nicaragua 2.9 2.7 13.1 13.1 1.1 1.1 11.7 11.6
Niger 2.5 4.1 21.9 22.4 1.9 3.4 22.1 22.5
Nigeria 1.8 2.5 12.5 12.2 1 1.5 12.1 11.8
Norway 2.7 2 29.1 26.8 0.89 0.64 29.5 24.3
Oman 1.6 1.7 9 9.7 0.62 0.69 9 9.7
Pakistan 2.4 2.8 18.1 18.2 1.3 1.6 16.3 16.5
Panama 2.4 2.1 16.4 15.5 0.8 0.73 12.6 11.4
Papua New Guinea 4.2 4.6 16.7 16.6 2.3 2.7 16.2 16.1
Paraguay 2.3 2.4 21.2 20.6 0.82 0.94 15.9 15.1
Peru 3.3 3 26.4 26 1.2 1.1 14.9 14.2
Philippines 4.5 4.7 34.1 34.3 1.6 1.7 25.9 26.4
Poland 9.5 6.4 49.8 47.9 2.6 1.7 36.4 32.4
Portugal 3.2 2.1 19.7 17.4 0.9 0.53 15.8 12.5
Puerto Rico 3.7 2.8 24.8 21.7 0.74 0.53 15.9 13.3
Qatar 1.8 1.8 19 23.4 0.82 0.82 17.4 22.4
Republic of Moldova 8.6 6.2 30.6 30.9 2.2 1.6 19.5 19.3
Romania 7.1 4.6 34.2 33.7 2 1.2 23.5 21.2
Russian Federation 7.4 5.2 34.3 34.8 2.1 1.5 23.1 22
Rwanda 0.67 0.92 9.9 10.1 0.39 0.61 9.6 9.8
Saint Lucia 0 0 15.9 16.1 0 0 11.9 12.1
Follows
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Based on the reported results for cancer in 2018, the 
highest incidence (8.6 per 1,000,000) and mortality 
(4.3 per 100,000) of the ovarian cancer are related to 
the very high HDI areas (Fig. 3).
The variance analysis detected the highest mean in-
cidence (8.4 out of 100,000) being related to very 
high HDI areas and the lowest incidence (3.4 out of 
100,000) related to low HDI areas, which was sta-
tistically significant (P  <  0.0001). Moreover, the 
highest mortality rate (4.8 per 100,000) was perti-
nent to very high HDI areas while the lowest (3.6 per 
100,000) was found for medium HDI areas; this dif-
ference was also statistically significant (P < 0.0001) 
(Tab. II).
Tab. I. Estimated age-standardized incidence and mortality rates due to ovarian cancer in the world in 2018 [source: GLOBOCAN 2018].
Country
Incidence Mortality
Age group Age group
0-49 50-85 0-49 50-85
CR ASR CR ASR CR ASR CR ASR
Samoa 1.3 1.7 23.1 25.3 1.3 1.7 69.4 53.2
Sao Tome and Principe 5.3 6.4 9.3 7.5 2.1 2.2 9.3 7.5
Saudi Arabia 1.5 1.3 12.2 13 0.54 0.48 9.6 10.5
Senegal 1.6 2.1 16.5 16.7 0.93 1.4 16.2 16.5
Serbia 10.5 7.4 51.4 53.1 2.4 1.6 29.9 27.3
Sierra Leone 1.3 1.8 11.5 11.7 0.82 1.2 11.5 11.7
Singapore 7 4.6 38.9 34 1.8 1.1 24.1 22.6
Slovakia 6.5 4.3 43.7 40.6 1.3 0.87 32.7 28
Slovenia 4.2 2.8 29.9 26.8 1.5 0.93 28.2 23
Solomon Islands 4.8 5.3 19.9 20.6 4.8 5.3 19.9 20.6
Somalia 2.3 3.5 23.4 23.9 1.8 3 23.7 24.2
South Africa 1.9 1.8 16.7 16.5 0.71 0.7 14.6 14.4
South Sudan 1.9 2.6 20.3 20.5 1.3 1.9 20.2 20.4
Spain 5.2 3.2 26.9 24.9 1.3 0.75 19.1 15.6
Sri Lanka 3.7 3.1 18.4 18.6 1.4 1.2 13 13
Sudan 2.1 2.7 23.4 23.8 1 1.5 23.1 23.6
Suriname 1.8 1.6 22.9 22.7 0 0 19.8 19.1
Swaziland 1.3 1.8 8.6 8.7 0.47 0.71 8.6 8.7
Sweden 2.5 1.9 25.7 24.4 0.3 0.21 26.2 18.2
Switzerland 3.1 2.1 27.2 21.2 0.83 0.53 23.1 15.2
Syrian Arab Republic 2.2 2.6 20.4 20.6 1 1.3 18.8 19.1
Tajikistan 1.2 1.3 8 8 0.41 0.49 7 7.3
Tanzania, United Republic of 0.55 0.77 7.9 8.1 0.31 0.52 7.8 8
Thailand 4.8 3.3 17.6 17.5 2.4 1.6 11.3 11.3
The Netherlands 2.1 1.6 31.2 25.6 0.87 0.61 28.5 22.6
The former Yugoslav Republic 
of Macedonia
6.6 4.8 26.3 26.2 1.5 1 15.4 14.2
Timor-Leste 1.9 2.8 17.6 17.7 0.86 1.5 14.9 15.2
Togo 1.5 2 13.3 13.3 0.86 1.2 13.1 13.1
Trinidad and Tobago 5.7 4.5 25 24.6 2 1.6 33.6 32.2
Tunisia 1.8 1.5 12.8 12.6 0.61 0.51 10.8 10.7
Turkey 3.7 3.1 25.5 25.1 1.1 0.94 18.3 17.5
Turkmenistan 3.4 3.3 10.1 9.8 1.6 1.6 9.8 9.6
Uganda 1.3 2.3 19.2 19.2 0.9 1.7 18.4 18.6
Ukraine 9.3 6.3 34.6 36.4 2.7 1.8 23.2 23.1
United Arab Emirates 1.5 1.3 23.3 27.7 0.58 0.5 17.8 22.2
United Kingdom 3.7 2.7 42.9 37.5 0.78 0.56 30.3 22.4
United States of America 3.6 2.8 34.3 31.1 0.78 0.61 21.8 17.9
Uruguay 3.2 2.6 30.3 27.2 1.5 1.2 24.9 21.4
Uzbekistan 1.6 1.5 11.2 11.4 0.64 0.63 7.8 8
Vanuatu 1.7 1.7 9.9 10.4 1.7 1.7 9.9 10.4
Venezuela, Bolivarian Republic of 3.2 3 21 21 1.1 1.1 14.7 14.6
Viet Nam 1.8 1.5 7 7.4 0.64 0.55 5.1 5.4
Yemen 1.2 1.5 7 6.9 0.68 0.97 6.7 6.6
Zambia 0.82 1.1 6.5 6.5 0.41 0.65 6.2 6.3
Zimbabwe 1.2 1.5 16.9 17 0.55 0.83 16.6 16.8
Follows
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Displayed by the results, there is a positive and signifi-
cant correlation between incidence (r = 0.409, P < 0.05) 
and ovarian cancer mortality (r = 0.193, P < 0.05) with 
HDI (Fig. 4).
The results demonstrated a positive and significant 
correlation between incidence with GNI (r  =  0.326, 
P  <  0.0001), MYS (r  =  0.503, P  <  0.0001), LEB 
(r = 0.42, P < 0.0001) and EYS (r = 0.439, P < 0.0001). 
Also a positive and significant correlation was identi-
fied between the ovarian cancer mortality with GNI 
(r = 0.169, P < 0.05), MYS (r = 0.249, P < 0.05), LEB 
(r = 0.163, P < 0.05) and EYS (r = 0.118, P < 0.05) 
(Tab. III).
The results of linear regression analysis illustrated that 
boosting one standard unit in mean years of schooling 
would escalate the incidence and mortality of ovarian 
cancer by 0.2 (P < 0.05). However, no statistically sig-
nificant relationship was identified between gross na-
Fig. 2. Map presenting (A) incidence and (B) mortality rates of ovarian cancer among women in the world in 2018 [source: GLOBOCAN 2018].
Fig 3. Distribution of incidence and mortality rates of ovarian cancer in terms of HDI [source: GLOBOCAN 2018].
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tional income per 1,000 capita, life expectancy at birth 
and expected years of schooling with the incidence and 
mortality of ovarian cancer (Tab. IV).
The results demonstrated the mean incidence and mortality 
rates in women over 50 being significantly higher than in 
those under 50 (P < 0.05) (Tab. V).
Fig 4. Human Development Index, incidence and mortality rates of ovarian cancer in the world in 2018.
Tab. II. Ovarian cancer incidence and mortality rate in different HDI regions in 2018.
HDI levels
Incidence rate Mortality rate
CR ASR CR ASR
Very high human development 14.7 8.4 10.1 4.8
High human development 8.7 6.7 5.6 4.1
Medium human development 4.5 5.1 2.9 3.6
Low human development 2.9 4.4 2.3 3.8
P-value (F-test) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
CR: Crude Rate; ASR: Age-Standardized Rates per 100,000.
Tab. III. Pearson correlation between HDI components and dependent variable.
HDI components
ASIR* ASMR*
r P-value r P-value
Gross national income per 1,000 capita 0.326 P < 0.0001 0.169 P < 0.05
Mean years of schooling 0.503 P < 0.0001 0.249 P < 0.05
Life expectancy at birth 0.420 P < 0.0001 0.163 P < 0.05
Expected years of schooling 0.439 P < 0.0001 0.118 P > 0.05
* Dependent variables: ASIR and ASMR.
Tab. IV. Effect of HDI components on ovarian cancer incidence and mortality in the world in 2018.
HDI components
Incidence Mortality
B CI 95% P-value B CI 95% P-value
HDI 7.6 (-5.6, 21) 0.2 1.1 (-7.1, 9.5) 0.7
Gross national income per 1,000 capita -0.004 (-0.04, 0.002) 0.7 -0.004 (-0.0001, 0.002) 0.6
Mean years of schooling 0.2 (-0.03, 0.5) 0.03 0.2 (0.03, 0.4) 0.02
Life expectancy at birth -0.01 (0.1, 0.09) 0.7 0.006 (0.06, 0.08) 0.8
Expected years of schooling -0.1 (0.4, 0.2) 0.4 -0.2 (-0.4, -0.01) 0.04
Tab. V. Incidence and mortality rates of ovarian cancer for different age groups in the world in 2018.
Incidence Mortality
Variable
CR ASR CR ASR
Mean ± SD P-value Mean ± SD P-value Mean ± SD P-value Mean ± SD P-value
Age group








50-85 21.6 ± 10.8 21.05 ± 10 17.7 ± 8.8 16.4 ± 8.1
CR: Crude Rate; ASR: Age-Standardized Rates.
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of societies, and statistics have constantly shown that most 
of the deaths from cancer occur in the developing countries. 
Our results also disclosed a positive correlation between 
HDI and ovarian cancer incidence (r = 0.409, P < 0.0001) 
as well as mortality (r = 0.0771, P < 0.05) in 2018.
Global cancer rates and the distribution of different types 
of cancer are clearly linked to HDI, and planners need to 
be vigilant about the continually changing features and pri-
orities of cancer as countries move toward higher levels of 
human development. 
The incidence of cancer in different geographical areas can 
partly be attributed to differences in lifestyle-related risk fac-
tors. Related risk factors in the developed countries include 
smoking, pattern of nutritional and reproductive behaviors, 
and infectious agents in the developing countries; however, 
the pattern of the disease is being under change [20].
The greater ovarian cancer incidence in countries with 
higher HDIs could be ascribed to appropriate infrastructure, 
optimal health care, use of modern medical equipment, 
high standards of living and screening for early detection of 
the disease. The reason for higher mortality in the develop-
ing countries pertains to lack of access to optimal health 
care, changing lifestyle and high diagnostic and therapeutic 
costs. HDI is the mean for normal indexes, which measures 
optimal lifestyle, knowledge, and life expectancy. 
The results of our study manifested a significant positive 
correlation between the incidence and mortality of ovarian 
cancer and GDP (living standards) (P < 0.05). In a study by 
Leitzmann et al., the findings revealed that obesity with its 
hormonal mechanism elevates the risk of ovarian cancer, 
and hence escalates death [21]. 
Socioeconomic status is one of the predictors of ovarian 
cancer incidence and maintenance. Access to health care, 
patient awareness of ovarian cancer symptoms, timely 
response to symptoms, lifestyle and underlying diseases 
justify the link between socioeconomic status and ovarian 
cancer [22, 23]. 
Our study could also indicate a positive and significant cor-
relation between life expectancy index and the incidence 
and mortality of ovarian cancer (P < 0.05). 
Most cancers seem to be more common in the elderly. 
Cancer is also associated with population aging and socio-
economic development. Further, the United Nations De-
velopment Program (UNDP) has now considered life ex-
pectancy as important [24, 25]. The Human Development 
Index (HDI) has also been taken into account to assess the 
impact of social development on health issues (including 
cardiovascular diseases and cancer) in different countries. 
Despite augmenting life expectancy and shrinking stand-
ardized mortality in men and women, the incidence of can-
cer has relatively remained stable [26]. The relationship be-
tween cancer and life expectancy in the general population 
has also been extensively studied [17, 27]
In addition to what was explained, the greater incidence 
of ovarian cancer in areas with higher life expectancy than 
those with lower and moderate levels could possibly indi-
cate an improvement in diagnosis. Nevertheless, over-di-
agnosis of the ovarian cancer can also play a role [26]. Our 
findings, additionally, demonstrated a significant positive 
correlation between education level and the incidence and 
Discussion
The results uncovered the highest ovarian cancer incidence 
in the world pertaining to Serbia (16.6 per 100,000), Brunei 
(16 per 100,000) and Belarus (15.4 per 100,000), respective-
ly. In addition, the highest death rate for ovarian cancer was 
related to Samoa (12 per 100,000), Solomon Islands (8.4 per 
100,000) and Poland (7.8 per 100,000), respectively. The 
highest ovarian cancer incidence reported for Asia amounts 
to (51.8%), followed by Europe (22.9%), North America 
(9.2%), Latin America (7.9%), Africa (7.4%) and Oceania 
(0.73%). The lowest incidence is pertinent to Oceania. 
Differences in the incidence of cancer in these areas can 
be attributed to variation in the economic situation of the 
individuals. An indicator for measuring a country’s condi-
tion is the human development index (HDI). This index 
examines the conditions of a country in three fundamental 
aspects of development including life expectancy, educa-
tion and living standard. Life expectancy is measured with 
life expectancy at birth, and years of potential education, 
and standards of living with per capita income or GDP. In 
countries with high levels of HDI, ovarian cancer incidence 
and mortality proves to be higher. Causes of high incidence 
include environmental and genetic factors, early screening, 
proper health care, early-stage disease diagnosis, and ac-
curate registration systems [18]. 
The incidence of ovarian cancer in the United States in 2015 
was 21,290 whereas the death rate levelled at 14,180. The 
cancer is reported as 11.4 percent for Eastern Europe and 
6% for Central Europe  [18]. Eighty-four percent of can-
cerous cases are reported for Asian countries. The highest 
standardized rate of ovarian cancer incidence is related to 
Asian countries such as Singapore and Kazakhstan. Stand-
ardized ovarian cancer mortality comprises five countries 
including India, China, Indonesia, Japan and Pakistan bear-
ing the highest rate of ovarian cancer mortality [16].
The results of our study identified a positive correlation 
between human development index and the incidence and 
mortality of ovarian cancer.
The results of Rahmani’s et al. study in 2018 revealed a 
significant positive relationship between the prevalence 
of ovarian cancer and HDI (p < 0.001)  [12]. A study by 
Momenimovahed et al. (2019) demonstrated that although 
the prevalence of ovarian cancer is higher in areas with 
higher HDI, it is inversely proportional to the mortality 
rate [19]. Moreover, a 2016 study by Razi et al. identified 
a significant positive relationship between HDI levels and 
ovarian cancer. Ovarian rates appear to be greater in high-
income individuals. The findings of the above study are in 
line with those of ours [1]. As these investigations project, 
cancer is still a global issue thereby requiring more exten-
sive and comprehensive probes [4]. 
Socio-economic changes have had profound effects on 
cancer incidence and mortality. In countries with low or 
average income, the risk of cancer exhibits a rising trend. 
Cancer-induced infections account for about 26% of can-
cers in low-income countries. Low physical activity levels, 
obesity, malnutrition, infant lactation and the affluent social 
class are known as some of the risk factors for ovarian can-
cer [19]. The disease is associated with the industrialization 
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mortality of the ovarian cancer (p < 0.05). Furthermore, in 
some investigations by Keng et al. [28] and Fallowfield et 
al. [29] a positive relationship was observed between ovar-
ian cancer awareness and education level. 
Because there is to date no effective way to prevent or screen 
ovarian cancer, early detection of the symptoms is of crucial 
importance. In countries where women enjoy greater levels 
of knowledge and education, there may be higher report of 
ovarian cancer incidence and mortality resulting from diag-
nosis of the disease, hence justifying this correlation.
As for some recent advancements and the fact that the true 
purpose of any development plan is achieving a healthy 
creative and happy life, HDI is needed to be considered. 
Genetic factors are known as the major causes of ovarian 
cancer. Therefore, early prevention strategies for the dis-
ease can be effective in reducing its incidence. Despite the 
relationship between these factors, caution must be taken 
regarding the interpretation and generalizability of the 
findings. In addition to the epidemiological risk factors of 
ovarian cancer, the inherent constraints of ecological stud-
ies should also be considered. On balance, it can be said 
that ovarian cancer incidence and mortality rate has seen 
a growing trend in many countries. Through adopting pre-
ventive measures, conducting epidemiological studies, per-
forming timely treatment, and monitoring patients affected 
with ovarian cancer particularly with individuals residing 
in less-developed countries, the burden of the disease could 
very likely be reduced and effective steps could also be tak-
en to improve the health systems of these countries. 
Conclusions
Given the positive and significant correlation between ovar-
ian cancer incidence and mortality with HDI, exercising at-
tention to risk factors in these countries can be effective in 
containing its incidence and mortality. Higher incidence in 
these countries may be due to better and earlier detection 
of the disease. It can, therefore, be said that life expectancy, 
education, and GDP are the factors virtually associated 
with the disease accordingly contributing to depress its in-
cidence and mortality.
Global cancer rates and the distribution of different types 
of cancer are clearly linked to HDI thus planners need to 
be vigilant about proceeding to change cancer features and 
priorities as countries move toward higher levels of human 
development. 
Limitations of the study
Limitations associated with our study largely comprise the 
data sources deployed. This is an ecological study special 
limitation of which include ecological misleading and lack 
of linkage between group results and the subjects.
Recommendations
Further research into the association between cancer (in-
cidence, mortality, and survival) and HDI is warranted, 
and research using specific HDI components may pro-
vide meaningful insights into the relative importance of 
each factor pertinent to cancer. In addition, examining the 
incidence and mortality of cancer with increasing human 
development index can lead to a better understanding of 
cancer patterns and the way they change in terms of the rate 
of human development. Research on cancer changes con-
sidering human development at the regional and national 
levels can shed light on the relative importance of social, 
economic, cultural, and environmental factors playing a 
role in the scale and characteristics of the disease.
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